Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Uric acid and the cardio‐renal effects of SGLT2 inhibitors
Clifford J. Bailey
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 6, pp. 1291-1298
Open Access | Times Cited: 162

Showing 1-25 of 162 citing articles:

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 583
Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9221-9221
Open Access | Times Cited: 336
Uric Acid and Oxidative Stress—Relationship with Cardiovascular, Metabolic, and Renal Impairment
Mihai-Emil Gherghina, Ileana Peride, Mirela Ţigliş, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3188-3188
Open Access | Times Cited: 237
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 230
Uric Acid and Hypertension: An Update With Recommendations
Laura Gabriela Sánchez‐Lozada, Bernardo Rodríguez‐Iturbe, Eric E. Kelley, et al.
American Journal of Hypertension (2020) Vol. 33, Iss. 7, pp. 583-594
Open Access | Times Cited: 161
Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease
Claudio Ponticelli, Manuel Alfredo Podestà, Gabriella Moroni
Kidney International (2020) Vol. 98, Iss. 5, pp. 1149-1159
Closed Access | Times Cited: 148
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Clifford J. Bailey, Caroline Day, Srikanth Bellary
Current Diabetes Reports (2022) Vol. 22, Iss. 1, pp. 39-52
Open Access | Times Cited: 140
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
Wolfram Doehner, Stefan D. Anker, Javed Butler, et al.
European Heart Journal (2022) Vol. 43, Iss. 36, pp. 3435-3446
Open Access | Times Cited: 85
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, Javed Butler, George L. Bakris, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 2, pp. 108389-108389
Open Access | Times Cited: 45
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 37
Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 26
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
J. Steen Jensen, Massar Omar, Caroline Kistorp, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 9, Iss. 2, pp. 106-116
Closed Access | Times Cited: 102
Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease
Niki Katsiki, George Dimitriadis, Dimitri P. Mikhailidis
Current Pharmaceutical Design (2021) Vol. 27, Iss. 16, pp. 1941-1951
Closed Access | Times Cited: 91
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care
Hyon K. Choi, Natalie McCormick, Chio Yokose
Nature Reviews Rheumatology (2021) Vol. 18, Iss. 2, pp. 97-111
Closed Access | Times Cited: 86
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 81
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, et al.
Current Heart Failure Reports (2021) Vol. 18, Iss. 5, pp. 315-328
Open Access | Times Cited: 77
Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
Victor Okunrintemi, Basem M. Mishriky, J.R. Powell, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 1, pp. 276-280
Closed Access | Times Cited: 76
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure
Shunsuke Tamaki, Takahisa Yamada, Tetsuya Watanabe, et al.
Circulation Heart Failure (2021) Vol. 14, Iss. 3
Open Access | Times Cited: 61
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Asmaa Elrakaybi, Katharina Laubner, Qian Zhou, et al.
Molecular Metabolism (2022) Vol. 64, pp. 101549-101549
Open Access | Times Cited: 57
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
Kirsty McDowell, Paul Welsh, Kieran F. Docherty, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 6, pp. 1066-1076
Open Access | Times Cited: 47
The Association of Excess Body Weight with Risk of ESKD Is Mediated Through Insulin Resistance, Hypertension, and Hyperuricemia
Josef Fritz, Wolfgang Brozek, Hans Concin, et al.
Journal of the American Society of Nephrology (2022) Vol. 33, Iss. 7, pp. 1377-1389
Open Access | Times Cited: 44
Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation
Go Anan, Takuo Hirose, Daisuke Kikuchi, et al.
Pharmacological Research (2022) Vol. 186, pp. 106524-106524
Open Access | Times Cited: 40
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 38
Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
Xin Chen, Carl‐Friedrich Hocher, Linghong Shen, et al.
AJP Cell Physiology (2023) Vol. 325, Iss. 3, pp. C661-C681
Closed Access | Times Cited: 32
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Ema Schönberger, Vjera Mihaljević, Kristina Steiner, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 17, pp. 6671-6671
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top